Literature DB >> 22867899

Human immunodeficiency virus infection and chronic myeloid leukemia.

Moosa Patel1, Vinitha Philip, Fatima Fazel, Atul Lakha, Alexander Vorog, Nazeer Ali, Alan Karstaedt, Sugeshni Pather.   

Abstract

CML (chronic myeloid leukaemia) in association with HIV (human immunodeficiency virus) infection (HIV-CML) is rarely described and is likely to be coincidental. The natural history and behaviour of HIV-CML is different, being more atypical and aggressive. Both conditions, and their respective treatments may cause myelosuppression. Concurrent treatment with cART (combination antiretroviral therapy) and the tyrosine kinase inhibitors (TKI's) can result in appropriate control of CML and HIV infection, as well as long term survival. However, drug interactions between ARV's and TKI's may require adjustment of treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867899     DOI: 10.1016/j.leukres.2012.07.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Lifelong TKI therapy: how to manage cardiovascular and other risks.

Authors:  Michael J Mauro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook.

Authors:  Katherine E Hodkinson; Nikki Bouwer; Jenifer Vaughan
Journal:  Afr J Lab Med       Date:  2022-05-31

Review 3.  Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV.

Authors:  Sara Rodríguez-Mora; Adam M Spivak; Matthew A Szaniawski; María Rosa López-Huertas; José Alcamí; Vicente Planelles; Mayte Coiras
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

Review 4.  Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection.

Authors:  Núria Climent; Montserrat Plana
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

5.  Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.

Authors:  Lorena Vigón; Paula Martínez-Román; Sara Rodríguez-Mora; Montserrat Torres; María C Puertas; Elena Mateos; María Salgado; Antonio Navarro; Matilde Sánchez-Conde; Juan Ambrosioni; Miguel Cervero; Christoph Wyen; Christian Hoffmann; José M Miró; José Alcamí; Daniel Podzamczer; Valentín García-Gutiérrez; Javier Martínez-Picado; Verónica Briz; María Rosa López-Huertas; Vicente Planelles; Mayte Coiras
Journal:  Biochem Pharmacol       Date:  2021-06-26       Impact factor: 6.100

6.  Hematologic malignancies in South Africa 2000-2006: analysis of data reported to the National Cancer Registry.

Authors:  Sara J Schonfeld; Friederike Erdmann; Tracey Wiggill; Elvira Singh; Patricia Kellett; Chantal Babb; Joachim Schüz
Journal:  Cancer Med       Date:  2016-01-15       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.